LEVETIRACETAM-AFT  levetiracetam 500 mg/5 mL concentrate solution for infusion vial Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam-aft levetiracetam 500 mg/5 ml concentrate solution for infusion vial

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - injection, concentrated - excipient ingredients: glacial acetic acid; sodium chloride; water for injections; sodium acetate trihydrate - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Levetiracetam SUN levetiracetam 500mg/5mL concentrated injection vials Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam sun levetiracetam 500mg/5ml concentrated injection vials

sun pharma anz pty ltd - levetiracetam, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: glacial acetic acid; water for injections; sodium chloride; sodium acetate trihydrate - levetiracetam (film-coated tablets and oral solution) is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam sun concentrated injection after dilution is an alternative for patients when oral administration is temporarily not feasible.

LEVETIRACETAM SANDOZ levetiracetam 500 mg /5 mL concentrate solution for IV infusion vial Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam sandoz levetiracetam 500 mg /5 ml concentrate solution for iv infusion vial

sandoz pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium acetate trihydrate; glacial acetic acid - levetiracetam sandoz concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.,levetiracetam sandoz concentrate solution for iv infusion is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with jme. ? add on therapy in the treatment of pgtc seizures in adults and children from 4 years of age with ige.

LEVETIRACETAM MEDSURGE levetiracetam 500 mg/5 mL concentrate solution for IV infusion vial Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam medsurge levetiracetam 500 mg/5 ml concentrate solution for iv infusion vial

medsurge pharma pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium chloride; sodium acetate trihydrate; glacial acetic acid; water for injections - levetiracetam concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.,levetiracetam concentrate solution for iv infusion is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation.,? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme).,? add on therapy in the treatment of primary generalised tonic-clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

LEVETIRACETAM IV ARX levetiracetam 500mg/5mL concentrate solution for IV infusion vial Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam iv arx levetiracetam 500mg/5ml concentrate solution for iv infusion vial

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: sodium acetate trihydrate; sodium chloride; water for injections; glacial acetic acid - levetiracetam concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and, add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

HOSPIRA LEVETIRACETAM CONCENTRATE FOR IV INFUSION levetiracetam 500 mg/5 mL concentrate for infusion vial Ástralía - enska - Department of Health (Therapeutic Goods Administration)

hospira levetiracetam concentrate for iv infusion levetiracetam 500 mg/5 ml concentrate for infusion vial

pfizer australia pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: nitrogen; sodium acetate trihydrate; sodium chloride; glacial acetic acid; water for injections - hospira? levetiracetam concentrate for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. levetiracetam is indicated for: use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy.

LEVETIRACETAM-AFT  levetiracetam 100 mg/mL oral solution bottle Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam-aft levetiracetam 100 mg/ml oral solution bottle

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

RWR CALM-P OILY INJECTION Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rwr calm-p oily injection

rwr veterinary products pty ltd - hydroxy progesterone hexanoate - parenteral liquid/solution/suspension - hydroxy progesterone hexanoate steroid-progestin active 100.0 mg/ml - endocrine system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - depot progesterone injection

LEVETIRACETAM GH Oral levetiracetam 100 mg/mL amber glass bottle Ástralía - enska - Department of Health (Therapeutic Goods Administration)

levetiracetam gh oral levetiracetam 100 mg/ml amber glass bottle

southern cross pharma pty ltd - levetiracetam, quantity: 100 mg/ml - solution - excipient ingredients: propyl hydroxybenzoate; purified water; ammonium glycyrrhizinate; acesulfame potassium; methyl hydroxybenzoate; sodium citrate dihydrate; glycerol; citric acid monohydrate; maltitol; flavour - levetiracetam gh oral solution is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment,of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary,generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12,years of age with juvenile myoclonic epilepsy (jme),,? add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and,children from 4 years of age with idiopathic generalized epilepsy (ige)